Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Othman Al-Sawaf

Othman Al-Sawaf

MD
University Hospital of Cologne
Fixed-duration treatment strategies for frontline and relapsed CLL 0:56
Fixed-duration treatment strategies for frontline and relapsed CLL
Othman Al-Sawaf • 16 Jun 2023
The expanding landscape of next-generation BTK inhibitors in CLL 1:26
The expanding landscape of next-generation BTK inhibitors in CLL
Othman Al-Sawaf • 16 Jun 2023
Treatment of Richter’s transformation: recent insights 1:47
Treatment of Richter’s transformation: recent insights
Othman Al-Sawaf • 16 Jun 2023
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL 1:43
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL
Othman Al-Sawaf • 16 Jun 2023
Latest advances in BTK inhibitors from EHA 2023
Lydia Scarfò et al. • 24 Jun 2023
6-year results of CLL14: venetoclax-obinutuzumab for previously untreated CLL 5:59
6-year results of CLL14: venetoclax-obinutuzumab for previously untreated CLL
Othman Al-Sawaf • 9 Jun 2023
The role of MRD as a prognostic & predictive biomarker in CLL 1:59
The role of MRD as a prognostic & predictive biomarker in CLL
Othman Al-Sawaf • 6 Oct 2022
CLL14: feasibility of fixed-duration frontline therapy in CLL 1:32
CLL14: feasibility of fixed-duration frontline therapy in CLL
Othman Al-Sawaf • 6 Oct 2022
Biomarker-guided therapy in CLL 1:43
Biomarker-guided therapy in CLL
Othman Al-Sawaf • 6 Oct 2022
MRD: a valuable tool in CLL 1:13
MRD: a valuable tool in CLL
Othman Al-Sawaf • 11 Jun 2022
Using MRD to better understand treatment responses in patients with CLL 1:04
Using MRD to better understand treatment responses in patients with CLL
Othman Al-Sawaf • 11 Jun 2022
Treatment options for CLL patients with poor prognostic markers 1:06
Treatment options for CLL patients with poor prognostic markers
Othman Al-Sawaf • 11 Jun 2022
5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL 0:59
5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL
Othman Al-Sawaf • 11 Jun 2022
CLL highlights at ASH 2020 2:09
CLL highlights at ASH 2020
Othman Al-Sawaf • 8 Dec 2020
Severe infections impact prognosis for CLL patients receiving CIT 3:46
Severe infections impact prognosis for CLL patients receiving CIT
Othman Al-Sawaf • 8 Dec 2020
CLL14: Venetoclax plus obinutuzumab for CLL 5:54
CLL14: Venetoclax plus obinutuzumab for CLL
Othman Al-Sawaf • 8 Dec 2020
The content of VJHemOnc is intended for healthcare professionals